Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Strides Shasun Ltd    STAR   INE939A01011

End-of-day quote. End-of-day quote  - 09/30
1006.9 INR   +0.69%
08/25 STRIDES SHASUN : receives USFDA Approval for Polyethylene Glycol 335..
08/24 STRIDES SHASUN : gets USFDA tentative nod for Ranitidine tablets
08/17 STRIDES SHASUN : Press Release - Q1 FY17
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Strides Arcolab Limited : Strides Arcolab Receives US FDA Nod To Commercialize First Liquid Injectable Product From Its New Facility

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2012 | 03:03am CEST

Press Release
Wednesday, April 13, 2011

Strides Arcolab Limited, Strides House, Bannerghatta Road, Bangalore - 560076, India

BSE: 532531

NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA NOD TO COMMERCIALIZE

FIRST LIQUID INJECTABLE PRODUCT FROM ITS NEW FACILITY

• First shipments to commence in April 2011

April 13, 2011, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received approval from the US FDA to commercialize the first liquid injection sterile product from the Company's new Sterile Injectable complex in Bangalore. The approved product has been facing prolonged shortage in the USA and approval from the new facility will offer Strides unconstrained capacities to meet the market demand.

With this approval, significant capacity will be released from the existing site enabling

Strides to commercialize additional liquid injectable products.

Strides had earlier announced approval for Vancomycin Injection from its new facility in Bangalore in a lyophilized format and the Company has already started supplies to the US market in March 2011.

Commenting on this development Venkat Iyer, CEO, Agila Specialties, said, "The US FDA approval for the product from the new site will go a long way in ameliorating product shortages in critical therapeutic areas. Two significant product approvals from the new facility augur well for the launch of a series of products in the USA during 2011"

For reasons of confidentiality, the Company is not in a position to disclose the name of the product.

About Agila Specialties

Agila Specialties Private Limited is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 7 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.
The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350- scientist strong global R&D Centre located in Bangalore.
Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

Strides

PR Consultancy

Mr. V.S. Iyer, CEO - Agila
+91 80 66580111
Mr. Kannan. N (Investors)
+91 98450 54745
Melissa Arulappan (Media)
+91 98450 22389
Corporate Voice | Weber Shandwick
Mahesh Nair,
+91 9880376648 maheshn@corvoshandwick.co.in
Hiba Kunil
+91 98807 26372 hiba@corvoshandwick.co.in

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on STRIDES SHASUN LTD
08/25 STRIDES SHASUN : receives USFDA Approval for Polyethylene Glycol 3350, Powder fo..
08/25 STRIDES SHASUN : Gets usfda nod for ulcer drug
08/24 STRIDES SHASUN : gets USFDA tentative nod for Ranitidine tablets
08/18 STRIDES SHASUN : To hive off api division
08/17 STRIDES SHASUN : Press Release - Q1 FY17
07/28 STRIDES SHASUN : Shareholding pattern
07/21 STRIDES ARCOLAB LIMITED : ex-dividend day for annual dividend
07/03 STRIDES SHASUN : Trailing twelve month results - strides shasun limited
07/03 STRIDES SHASUN : Quarterly results - strides shasun limited
07/02 STRIDES SHASUN : Facility is fda-compliant
More news
Sector news : Generic Pharmaceuticals
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30 GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery case
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30DJSHIRE : Files 8K - Other Events
09/30DJNovo Nordisk Announces Job Cuts
More sector news : Generic Pharmaceuticals
Advertisement
Financials ( INR)
Sales 2017 41 108 M
EBIT 2017 6 095 M
Net income 2017 4 164 M
Debt 2017 18 589 M
Yield 2017 0,47%
P/E ratio 2017 21,64
P/E ratio 2018 16,41
EV / Sales 2017 2,64x
EV / Sales 2018 2,25x
Capitalization 89 898 M
More Financials
Chart STRIDES SHASUN LTD
Duration : Period :
Strides Shasun Ltd Technical Analysis Chart | STAR | INE939A01011 | 4-Traders
Full-screen chart
Technical analysis trends STRIDES SHASUN LTD
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 1 247  INR
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Shashank Sinha Chief Executive Officer
Deepak Calian Vaidya Chairman
Badree Komandur CFO, Secretary, Chief Compliance Officer & EVP
Sunil Nadkarni Chief Technical Services Officer
Arun N. Kumar Executive Vice Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
STRIDES SHASUN LTD-22.15%1 349
SUN PHARMACEUTICAL IND..-9.55%26 832
OTSUKA HOLDINGS CO LTD5.86%25 253
ONO PHARMACEUTICAL CO...-35.02%16 314
BIOMARIN PHARMACEUTICA..-11.68%15 801
ASPEN PHARMACARE HOLDI..2.12%10 320
More Results